Clinical Trials Logo
  1. Home
  2. Glaucoma, Primary Open Angle
  3. NCT03675412

Caffeine Consumption in Glaucoma Patients and Healthy Subjects

Glaucoma, Primary Open Angle Clinical Trial

Official title:
Acute Changes in Optic Nerve Head (ONH) and Macular Blood Flow After Caffeine Consumption in Glaucoma Patients and Healthy Subjects: A Quantitative Optic Coherence Tomography Angiography (OCTA) Study

Clinical Trial Summary

Caffeine is the most widely consumed drinking nutrient in the world. Caffeine effects various organs and the vascular system. It decreases ocular blood flow due to vasoconstriction.

Clinical Trial Description

Ingestion of caffeine in glaucoma patients and healthy subjects may decrease peripapillary and macular blood flow in the back of the eye. The primary objective of this study is to assess the acute changes in peripapillary and macular blood flow before and after an intake of oral caffeine (200 milligram tablet) in glaucoma patients and healthy subjects by using optical coherence tomography angiography (OCTA) scans. This novel imaging tool creates three-dimensional angiograms to assesses signal changes caused by flowing blood cells in a non-invasive angiogram scan. Blood flow is shown as vessel density measured in percentage. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03675412
Study type Interventional
Source Wills Eye
Contact M. Reza Razeghinejad, MD
Phone 215-928-7023
Email mrazeghi@willseye.org
Status Recruiting
Phase N/A
Start date December 30, 2018
Completion date December 31, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02679482 - Following Patients After Selective and Pascal Laser Trabeculoplasty for Treatment of Chronic Open-Angle Glaucoma N/A
Recruiting NCT05999006 - Safety and Feasibility of the ELIOS System in POAG Patients N/A
Completed NCT05181046 - Evaluation of Nanodropper-mediated Microdrops vs. Standard Drops of 0.5% Timolol Maleate in Glaucoma Patients N/A
Completed NCT01999348 - A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting
Completed NCT04149899 - Safety and IOP-Lowering Effects of WB007 Phase 1/Phase 2
Not yet recruiting NCT04007276 - The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients Phase 4
Completed NCT01814761 - A Study of Bimatoprost 0.01% in the Clinical Setting Phase 4
Active, not recruiting NCT04899063 - Excimer Laser Trabeculostomy Glaucoma Treatment Study N/A
Completed NCT05474716 - The Effect of Topical Brimonidine on the Ocular Hemodynamics in Patients of POAG Using OCTA Phase 4
Recruiting NCT03067415 - Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily Phase 2
Not yet recruiting NCT06053307 - Treating Psychosocial Distress in Glaucoma N/A
Completed NCT02796560 - Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Phase 4
Terminated NCT02858284 - Evaluation of Safety and Efficacy of TUG (Therapeutic Ultrasound for Glaucoma) in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension N/A
Recruiting NCT05370287 - Adaptive Optics Retinal Imaging N/A
Not yet recruiting NCT05673954 - Glaucoma Assessment Via Reading Ability
Active, not recruiting NCT03318510 - LSFG in Patients With Normal Tension Glaucoma Tension Glaucoma N/A
Active, not recruiting NCT03151577 - Longitudinal Study on Glaucoma Surgery Using XEN® Gel Stent N/A
Completed NCT04465864 - Investigate, Following Cataract Surgery With IOL in Conjunction With Intracanalicular Dexamethasone Insert Phase 4
Completed NCT01833741 - A Study of LUMIGAN® RC in the Clinical Setting Phase 4
Completed NCT03800589 - Assessment of Effectiveness Ex-Press Surgery Modification N/A